StockData

Aquestive Therapeutics vs Tonix Pharmaceuticals

AQST and TNXP side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How AQST and TNXP compare

Aquestive Therapeutics is the larger company, worth 9.2 times as much as Tonix Pharmaceuticals ($464M against $50.4M).

Tonix Pharmaceuticals grew revenue faster over the last twelve months (196% versus 22.6% for Aquestive Therapeutics).

Aquestive Therapeutics keeps more of each dollar of sales as profit, with a net margin of −145% compared with −549% at Tonix Pharmaceuticals.

Tonix Pharmaceuticals scores higher on the StockData Score (10 against 3 for Aquestive Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricAQSTTNXP
Size and price
Market cap$464M$50.4M
Share price$3.70$2.94
Change, 1 year−31.4%−81.5%
Change, 5 years−41.9%−100.0%
Beta (5Y)1.200.75
Employees147142
StockData Score
Total score310 (better)
Valuation score03 (better)
Growth score22
Performance score00
Health score15 (better)
Dividend score00
Valuation
P/S8.6×1.7× (better)
P/B–0.2×
FCF yield−9.9% (better)−314%
Fair value–$16.91
Margin of safety–82.6%
Growth
Revenue growth (TTM)22.6%196% (better)
Revenue growth, 5Y average−0.58%–
Profitability
Gross margin67.0%83.8% (better)
Operating margin−97.5% (better)−568%
Net margin−145% (better)−549%
FCF margin−85.0% (better)−543%
Return on equity–−81.8%
Return on invested capital–−298%
Financial health
Debt / equity–0.00
Interest coverage−4.7×–
Current ratio7.19 (better)6.61
Altman Z-score−3.57 (better)−5.42
Piotroski F-score26 (better)
Dividends and buybacks
Buyback yield–−427%
Shareholder yield0.00% (better)−427%
Ownership
Held by institutions57.4%54.6%
Held by insiders3.2%0.27%
Insider net buying, 12 months−$2.3M$479K (better)
Short interest, % of float24.1%19.4%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.